HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy.

Abstract
We have developed an efficient, reproducible, and scaleable cell culture process for a recombinant adenoviral vector expressing therapeutic transgenes for clinical trials. HEK 293 cells - which support the propagation of E1 deficient adenovirus - were first adapted to serum free media and suspension growth. Subsequent studies focused on the infection, virus production and harvest from suspension culture bioreactors. Future studies are planned to address the kinetics of adenovirus production in HEK 293 as well as in other cell lines.
AuthorsG Schoofs, T J Monica, J Ayala, J Horwitz, T Montgomery, G Roth, F J Castillo
JournalCytotechnology (Cytotechnology) Vol. 28 Issue 1-3 Pg. 81-9 (Nov 1998) ISSN: 0920-9069 [Print] United States
PMID19003410 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: